Profile data is unavailable for this security.
About the company
Revance Therapeutics, Inc. is a commercial stage biotechnology company. The Company is focused on advanced aesthetic and therapeutic offerings, including neuromodulator product, DaxibotulinumtoxinA for Injection. The DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a purified botulinum toxin that does not contain human or animal-based components. The Company is also evaluating additional aesthetic and therapeutic indications for DaxibotulinumtoxinA for Injection including the full upper face, which includes glabellar lines, forehead lines and crow’s feet, and adult upper limb spasticity. It offers products and services for United States aesthetics practices, including the resilient hyaluronic acid (RHA) Collection of dermal fillers and OPUL. The RHA Collection of dermal fillers is a dermal filler for the correction of dynamic facial wrinkles and folds. OPUL’s product offering includes the point-of-sale platform, software and hardware terminal.
- Revenue in USD (TTM)99.32m
- Net income in USD-263.25m
- Incorporated1999
- Employees495.00
- LocationRevance Therapeutics Inc1222 Demonbreun Street, Suite 2000NASHVILLE 37203United StatesUSA
- Phone+1 (615) 724-7755
- Fax+1 (302) 674-5266
- Websitehttps://www.revance.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ImmunoGen, Inc. | 89.44m | -160.68m | 1.16bn | 106.00 | -- | 4.69 | -- | 13.10 | -0.6907 | -0.6907 | 0.3837 | 1.13 | 0.2472 | -- | 25.49 | 843,792.40 | -44.40 | -35.82 | -62.24 | -48.56 | -- | -- | -179.64 | -121.91 | -- | -23.28 | 0.00 | -- | -47.20 | -- | -213.94 | -- | -- | -- |
| Aclaris Therapeutics Inc | 6.14m | -83.27m | 1.18bn | 75.00 | -- | 4.78 | -- | 183.48 | -1.33 | -1.33 | 0.0983 | 3.54 | 0.0217 | -- | 7.79 | 81,880.00 | -29.42 | -45.25 | -31.14 | -50.38 | 27.19 | 23.19 | -1,355.98 | -1,612.49 | -- | -- | 0.00 | -- | 4.30 | -- | -77.63 | -- | 5.83 | -- |
| Morphic Holding Inc | 75.30m | -51.09m | 1.19bn | 101.00 | -- | 3.31 | -- | 17.05 | -1.43 | -1.43 | 2.00 | 10.09 | 0.1765 | -- | 64.08 | 745,524.80 | -11.97 | -- | -12.79 | -- | -- | -- | -67.85 | -- | -- | -- | 0.00 | -- | -55.96 | -- | -112.32 | -- | -- | -- |
| Merus NV | 52.72m | -53.88m | 1.22bn | 121.00 | -- | 3.70 | -- | 22.91 | -1.30 | -1.30 | 1.26 | 7.12 | 0.1279 | -- | 13.91 | 435,677.70 | -13.07 | -24.71 | -15.40 | -29.16 | -- | -- | -102.21 | -178.24 | -- | -- | 0.00 | -- | 64.00 | 77.64 | 21.86 | -- | 9.66 | -- |
| Chinook Therapeutics Inc | 54.36m | -92.48m | 1.23bn | 138.00 | -- | 2.54 | -- | 23.73 | -1.69 | -1.69 | 1.00 | 8.07 | 0.1077 | -- | 30.35 | 393,876.80 | -18.33 | -22.27 | -19.35 | -24.07 | -- | -- | -170.15 | -441.76 | -- | -20.80 | 0.00 | -- | 6,142.44 | 0.3698 | -26.11 | -- | -39.87 | -- |
| Editas Medicine Inc | 31.80m | -184.49m | 1.24bn | 264.00 | -- | 2.74 | -- | 40.10 | -2.70 | -2.70 | 0.4647 | 6.77 | 0.0476 | -- | 60.92 | 120,450.80 | -27.60 | -28.88 | -29.89 | -32.06 | -- | -- | -580.16 | -368.55 | -- | -- | 0.00 | -- | -71.85 | 33.37 | -65.98 | -- | 17.96 | -- |
| Madrigal Pharmaceuticals Inc | 0.00 | -255.90m | 1.24bn | 71.00 | -- | 15.10 | -- | -- | -15.07 | -15.07 | 0.00 | 4.88 | 0.00 | -- | -- | 0.00 | -94.02 | -37.85 | -126.80 | -41.31 | -- | -- | -- | -- | -- | -926.16 | 0.3681 | -- | -- | -- | -19.58 | -- | 132.44 | -- |
| Revance Therapeutics Inc | 99.32m | -263.25m | 1.27bn | 495.00 | -- | -- | -- | 15.80 | -3.84 | -3.84 | 1.45 | -0.036 | 0.1652 | 3.34 | 31.88 | 200,654.50 | -43.77 | -50.56 | -49.33 | -56.28 | 68.60 | -- | -265.04 | -1,010.99 | 3.20 | -31.54 | 1.01 | -- | 407.65 | 203.93 | 0.2762 | -- | 44.10 | -- |
| Taro Pharmaceutical Industries Ltd. | 570.90m | 91.11m | 1.28bn | 1.46k | 14.22 | 0.7558 | 11.01 | 2.27 | 2.42 | 2.42 | 15.19 | 45.59 | 0.2519 | 1.37 | 2.37 | 392,370.40 | 4.02 | 3.42 | 5.31 | 3.99 | 52.03 | 61.51 | 15.96 | 12.78 | 3.02 | -- | -- | 0.00 | 2.25 | -8.59 | 115.07 | -33.75 | 25.45 | -- |
| USANA Health Sciences, Inc. | 1.08bn | 89.28m | 1.29bn | 1.98k | 15.20 | 3.28 | 16.56 | 1.23 | 4.54 | 4.54 | 54.94 | 21.04 | 1.88 | 2.35 | -- | 545,496.40 | 15.53 | 20.34 | 20.69 | 27.86 | 81.08 | 82.30 | 8.27 | 9.98 | 1.93 | -- | -- | 0.00 | 4.57 | 3.35 | -6.54 | 3.09 | -17.15 | -- |
| Vericel Corp | 155.22m | -16.45m | 1.29bn | 281.00 | -- | 7.32 | -- | 8.25 | -0.35 | -0.35 | 3.31 | 3.71 | 0.6651 | 3.65 | 4.75 | 552,373.70 | -7.05 | -5.85 | -7.87 | -6.74 | 66.00 | 65.61 | -10.60 | -7.18 | 5.56 | -- | 0.0004 | -- | 25.77 | 23.49 | -360.86 | -- | 41.10 | -- |
| Petro Usa Inc | 0.00 | -9.15k | 1.30bn | -- | -- | -- | -- | -- | -0.296 | -0.296 | 0.00 | -3.60 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -40.59 | -- | -- | -- | -- | -61.48 | -- | -- | -- |
| Hims & Hers Health Inc | 320.88m | -72.51m | 1.31bn | 398.00 | -- | 4.28 | -- | 4.40 | -0.3622 | -0.3622 | 1.61 | 1.59 | 0.8816 | 9.83 | 100.20 | 806,226.10 | -19.92 | -- | -21.98 | -- | 74.48 | -- | -22.60 | -- | 4.53 | -- | 0.00 | -- | -- | -- | -3,430.95 | -- | -- | -- |
| Syndax Pharmaceuticals Inc | 138.95m | 818.00k | 1.36bn | 59.00 | 153.21 | 3.74 | 1,582.24 | 9.77 | -0.0331 | -0.0331 | 2.41 | 6.42 | 0.4151 | -- | 19.93 | 2,355,102.00 | 0.2444 | -27.65 | 0.2663 | -30.65 | -- | -- | 0.5887 | -163.32 | -- | 1.59 | 0.0529 | -- | 9,109.56 | 158.09 | 132.34 | -- | -13.15 | -- |
| Exscientia PLC (ADR) | -100.00bn | -100.00bn | 1.37bn | 287.00 | -- | 2.19 | -- | -- | -- | -- | -- | 5.57 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 9.55 | -- | 0.0125 | -- | 182.87 | -- | -120.94 | -- | -- | -- |
| Medifast Inc | 1.66bn | 156.90m | 1.39bn | 984.00 | 9.54 | 10.93 | 8.62 | 0.8518 | 13.47 | 13.47 | 142.71 | 11.75 | 4.72 | 3.58 | -- | 1,689,189.00 | 44.52 | 40.99 | 86.53 | 64.91 | 72.76 | 74.68 | 9.44 | 10.78 | 0.4588 | 462.02 | 0.1726 | 47.61 | 63.25 | 40.93 | 59.47 | 55.86 | 64.09 | 39.63 |
Data as of Aug 19 2022. Currency figures normalised to Revance Therapeutics Inc's reporting currency: US Dollar USD
45.70%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Jun 2022 | 4.81m | 6.60% |
| Palo Alto Investors LPas of 31 Mar 2022 | 4.42m | 6.07% |
| JPMorgan Investment Management, Inc.as of 30 Jun 2022 | 4.27m | 5.87% |
| GIC Pte Ltd. (Investment Management)as of 31 Dec 2021 | 4.18m | 5.74% |
| The Vanguard Group, Inc.as of 30 Jun 2022 | 3.53m | 4.85% |
| Capital Research & Management Co. (World Investors)as of 31 Mar 2022 | 3.35m | 4.60% |
| Polar Capital LLPas of 31 Mar 2022 | 2.46m | 3.38% |
| Franklin Advisers, Inc.as of 30 Jun 2022 | 2.33m | 3.21% |
| JPMorgan Asset Management (UK) Ltd.as of 30 Jun 2022 | 2.15m | 2.96% |
| Jennison Associates LLCas of 30 Jun 2022 | 1.76m | 2.41% |
More ▼
Data from 31 Mar 2022 - 02 Aug 2022Source: FactSet Research Systems Inc.
